Table 37: Statistical Comparisons of Pharmacokinetic Parameter Estimates Between Test and Historical Reference Treatments for EVG
Overall and by EVG Dose (50 mg vs. 85 mg)
Intensive PK Analysis Set: EVG

| Parameters | Treatment | | | | Statistical Comparison | | | |
| | Test | | Reference | | Ratio | | 90% Confidence Interval | Model |
	n	GLS Mean	n	GLS Mean	Test/Reference	(%)	(%)	rMSE

Analyte: EVG Pediatric Subjects (50 & 85 mg) in 183-0160 vs. Adults in 183-0145								

AUCtau (h*ng/mL)	14	22940.85	334	16902.03	Test/Reference	135.73	(116.24,158.49)	0.358

GLS Mean = Geometric Least Squares Mean.
PK parameters for the test group were from Study 183-0160 and for the reference group were estimated from population PK modeling in Study 183-0145.
All subjects in Part A, Cohort 2 received atazanavir/r or lopinavir/r as their background regimen.
For subjects receiving atazanavir/r or lopinavir/r, the EVG dose will be 50 mg for subjects >= 17 to < 30 kg and 85 mg for subjects >= 30 kg.
This summary includes Cohort 2 Part A subjects (12 with Screening HIV-1 RNA < 50 copies/mL and 2 with Screening HIV-1 RNA > 1000 copies/mL).
The Model rMSE was chosen as the maximum of the MSE from the test group and the reference group.